NASDAQ: UTHRUnited Therapeutics Revenue
United Therapeutics revenue was $3.18B for the trailing 12 months ending Dec 31, 2025, with 14% growth year over year. Quarterly revenue for the quarter (Q4 2025) ending on Dec 31, 2025 was $790.2M, down 1.2% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, UTHR annual revenue was $3.2B, with 10.6% growth year-over-year.
UTHR past revenue growth
How has UTHR's revenue growth performed historically?
Company
10.61%
Industry
379.98%
Market
88.6%
UTHR's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
UTHR's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
UTHR's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance
UTHR revenue history
Current Revenue
$3.2B
Current Earnings
$1.3B
Current Profit Margin
41.9%
UTHR's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance
Be the first to know when UTHR announces revenue.
UTHR Revenue History By Year
| UTHR Yearly Revenue | UTHR Revenue | UTHR Change | UTHR Revenue Growth |
|---|---|---|---|
| 2025-12-31 | $3.18B | $305.30M | +10.61% |
| 2024-12-31 | $2.88B | $549.90M | +23.63% |
| 2023-12-31 | $2.33B | $391.20M | +20.20% |
| 2022-12-31 | $1.94B | $250.80M | +14.88% |
| 2021-12-31 | $1.69B | $202.20M | +13.63% |
| 2020-12-31 | $1.48B | $34.50M | +2.38% |
| 2019-12-31 | $1.45B | -$179.00M | -11.00% |
| 2018-12-31 | $1.63B | -$97.50M | -5.65% |
| 2017-12-31 | $1.73B | $126.50M | +7.91% |
| 2016-12-31 | $1.60B | $133.00M | +9.07% |
| 2015-12-31 | $1.47B | $177.30M | +13.76% |
| 2014-12-31 | $1.29B | $171.52M | +15.36% |
| 2013-12-31 | $1.12B | $200.91M | +21.93% |
| 2012-12-31 | $916.08M | $172.89M | +23.26% |
| 2011-12-31 | $743.18M | $150.28M | +25.35% |
| 2010-12-31 | $592.90M | $234.02M | +65.21% |
| 2009-12-31 | $358.88M | $77.38M | +27.49% |
| 2008-12-31 | $281.50M | $70.55M | +33.45% |
| 2007-12-31 | $210.94M | $51.31M | +32.14% |
| 2006-12-31 | $159.63M | $43.72M | +37.71% |
| 2005-12-31 | $115.92M | $42.33M | +57.51% |
| 2004-12-31 | $73.59M | $20.25M | +37.96% |
| 2003-12-31 | $53.34M | $23.22M | +77.09% |
| 2002-12-31 | $30.12M | $24.39M | +425.56% |
| 2001-12-31 | $5.73M | $3.68M | +179.70% |
| 2000-12-31 | $2.05M | $1.61M | +369.42% |
| 1999-12-31 | $436.50k | $382.75k | +712.08% |
| 1998-12-31 | $53.75k | -$62.16k | -53.63% |
| 1997-12-31 | $115.91k | N/A | N/A |
United Therapeutics Revenue FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.